Pfizer Inc (PFE.BE)
Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
As of 08:08AM CEST. Market open.
| Previous close | 25.45 |
| Open | 25.45 |
| Bid | 25.54 x 0 |
| Ask | 25.57 x 0 |
| Day's range | 25.45 - 25.45 |
| 52-week range | 23.64 - 35.50 |
| Volume | |
| Avg. volume | 66 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Pfizer (PFE) closed at $27.41, marking a +1.59% move from the previous day.
- Barrons.com
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
Pfizer currently dominates the market for pneumococcal vaccines, which protect against bacterial infections that can cause pneumonia and meningitis, among other conditions. Merck, however, has been nipping at Pfizer’s heels for years. The company sells Vaxneuvance and Pneumovax 23, pneumococcal vaccines with combined 2023 revenue of $1.1 billion.
- Zacks
Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
© 2024 Yahoo. All rights reserved.